SCHEMBL6802993

SCHEMBL6802993

O=C(O)Cn1c(-c2ccc(Cl)cc2)ncc(NC(=O)c2ccccc2)c1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.52
MAPT P10636 2/20 0.52
NPC1 O15118 1/20 0.52
CYP1A2 P05177 1/20 0.52
CYP2C19 P33261 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
ELANE P08246 3/20 0.49
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47
LMNA P02545 1/20 0.47
HPGD P15428 1/20 0.47
P2RX3 P56373 1/20 0.46
KCNMA1 Q12791 1/20 0.44
CASP1 P29466 1/20 0.44
SUCNR1 Q9BXA5 1/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
PTGDR2 Q9Y5Y4 1/20 0.43
PRSS12 P56730 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6240974 0.96 RAB9A (0.55) RAB9AMAPTNPC1CYP1A2CYP2C19
SCHEMBL6240894 0.92 ELANE (0.51) RAB9AMAPTNPC1CYP1A2CYP2C19
SCHEMBL6805801 0.90 RAB9A (0.53) RAB9AMAPTNPC1SMN1; SMN2ELANE
SCHEMBL6805612 0.89 HDAC2 (0.46) RAB9AMAPTNPC1SMN1; SMN2ELANE
SCHEMBL6803430 0.89 ALDH1A1 (0.52) RAB9AMAPTNPC1SMN1; SMN2ELANE
SCHEMBL6799310 0.86 RAB9A (0.54) RAB9ANPC1SMN1; SMN2ELANEKDM4E
SCHEMBL6803975 0.85 ELANE (0.51) RAB9AMAPTNPC1SMN1; SMN2ELANE
SCHEMBL6803676 0.84 RAB9A (0.52) RAB9ANPC1SMN1; SMN2ELANECASP1
SCHEMBL6556407 0.82 ELANE (0.69) ELANEP2RX3
SCHEMBL6239384 0.82 RAB9A (0.48) RAB9AMAPTNPC1CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040063936-A1 Pyrimidine derivatives and process for preparing the same ONO PHARMACEUTICAL CO., LTD. (JP) 2004-04-01 US claimed
EP-1346985-A1 PYRIMIDINE DERIVATIVES AND PROCESS FOR PREPARING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2003-09-24 EP claimed
US-20040063936-A1 Pyrimidine derivatives and process for preparing the same ONO PHARMACEUTICAL CO., LTD. (JP) 2004-04-01 US disclosed
EP-1346985-A1 PYRIMIDINE DERIVATIVES AND PROCESS FOR PREPARING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2003-09-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063936-A1 Pyrimidine derivatives and process for preparing the same DPYD, NUDT1, UMPS RAB9A 2244/4885MAPT 3790/4885NPC1 1638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.